← Back to Clinical Trials
Recruiting NCT02245763

NCT02245763 STS/ACC TVT Registry Mitral Module

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02245763
Status Recruiting
Phase
Sponsor American College of Cardiology
Condition Mitral Valve Regurgitation
Study Type OBSERVATIONAL
Enrollment 4,000 participants
Start Date 2013-11
Primary Completion 2030-12

Eligibility & Interventions

Sex All sexes
Min Age 1 Year
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Leaflet Clip

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 4,000 participants in total. It began in 2013-11 with a primary completion date of 2030-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The TVT Registry™ is a benchmarking tool developed to track patient safety and real-world outcomes related to the transcatheter mitral valve repair (TMVR) procedure. Created by The Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC), the TVT Registry is designed to monitor the safety and efficacy of this new procedure for the treatment of mitral valve disease.

Eligibility Criteria

Inclusion Criteria: * All patients Exclusion Criteria: * Patients who cannot tolerate procedural anticoagulation or post procedural anti-platelet regimen * Active endocarditis of the mitral valve * Rheumatic mitral valve disease * Evidence of intracardiac, inferior vena cava (IVC) or femoral venous thrombus

Contact & Investigator

Central Contact

Joan K Michaels, RN

✉ jmichael@acc.org

📞 202-375-6309

Frequently Asked Questions

Who can join the NCT02245763 clinical trial?

This trial is open to participants of all sexes, aged 1 Year or older, studying Mitral Valve Regurgitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02245763 currently recruiting?

Yes, NCT02245763 is actively recruiting participants. Contact the research team at jmichael@acc.org for enrollment information.

Where is the NCT02245763 trial being conducted?

This trial is being conducted at Washington D.C., United States.

Who is sponsoring the NCT02245763 clinical trial?

NCT02245763 is sponsored by American College of Cardiology. The trial plans to enroll 4,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology